Solstice Oncology Raises $225M for Cancer Therapy

Solstice Oncology has officially launched, backed by a substantial $225 million Series A financing round. The significant capital infusion was spearheaded by RA Capital Management, with crucial participation from prominent venture capital firms Canaan Partners and Forbion, alongside other key investors. This funding positions Solstice to aggressively advance its novel immuno-oncology pipeline, with a strategic focus on intervening in cancer treatment at its earliest stages.

The company's core development program centers on porustobart, a next-generation, Fc-enhanced CTLA-4 antibody. Solstice Oncology is pioneering the use of this therapy in the neoadjuvant setting, aiming to treat cancer before surgery when the immune system is more robust and the disease has not yet developed significant resistance. This approach represents a significant shift in oncology treatment paradigms, moving beyond late-stage interventions.

Porustobart is currently being evaluated across two distinct clinical indications. One program is specifically targeting microsatellite-stable (MSS) clinical stage II-III colon cancer. The second indication remains undisclosed, suggesting a broader potential application for the therapy. The company is preparing to initiate enrollment for a pivotal Phase 2 study in early Q4 2026, which will investigate porustobart in combination with pembrolizumab for MSS colon cancer patients receiving neoadjuvant therapy.

Originally discovered and developed by Harbour BioMed, porustobart was licensed to Solstice Oncology in February 2026. This partnership granted Solstice exclusive rights for the development and commercialization of the therapy outside of Greater China. Harbour BioMed's prior research demonstrated promising results; a Phase 2 trial combining porustobart with tislelizumab in late-line MSS metastatic colorectal cancer patients without liver metastases achieved a 30% objective response rate, with a median duration of response lasting 8.4 months.

The strategic decision to focus on the neoadjuvant setting is driven by the belief that intervening earlier offers the greatest potential for improving cure rates and long-term survival. As stated by Caroline Loew, PhD, CEO of Solstice Oncology, "Treating patients early with an immuno-oncology combination therapy... could allow the immune response to act systemically, reaching micrometastatic disease well beyond the primary tumor." The company has moved with notable speed, having already filed and cleared an Investigational New Drug (IND) application.

Solstice Oncology anticipates releasing data from its upcoming Phase 2 program in the second half of 2027. This timeline is critical for validating the efficacy of porustobart in the neoadjuvant setting and will be closely watched by the broader oncology investment community. The substantial Series A funding underscores investor confidence in Solstice's strategy and the therapeutic potential of porustobart, particularly within the rapidly expanding field of immuno-oncology, which is projected to see significant growth driven by advancements in targeted therapies and combination treatments.